SCNX — Scienture Holdings, Inc.
NASDAQ · Healthcare · Pharmaceutical Retailers
$0.37
+$0.01 (+2.15%)
Scienture Holdings, Inc. (SCNX) is a pharmaceutical retailers company listed on NASDAQ. It is led by Shankar Hariharan Ph.D., based in 20 Austin Boulevard, Commack, NY, United States, 11725, with about 4 employees. Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Latest reported SCNX revenue for 2025-09-30 was $590.0K. Net income was -$3.6M. Revenue was up 5652.1% from 2025-06-30 to 2025-09-30. SCNX currently screens at market cap $15.8M.
Use this SCNX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SCNX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SCNX SEC filings page. Lician reads the product cache first so this HTML stays unique to Scienture Holdings, Inc. even when a live quote feed is slow.
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
SCNX Key Statistics
Market Cap
$15.76M
Volume
324,389
Previous Close
$0.43
Day Range
$0.41 – $0.45
P/B Ratio
0.23
EPS
$2.48
Revenue
$136.64K
Net Income
$9.07M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-90.0%
Profit Margin
6634.7%
Employees
4
SCNX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $136.64K | $1.36M | $10.25M | $9.89M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $9.07M | -$17.84M | -$3.91M | -$5.32M |
| EPS (Diluted) | $2.48 | -$23.35 | -$6.13 | -$0.65 |
Total Assets
$104.85M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$308.10K
Operating Cash Flow
-$14.27M
Free Cash Flow
$0.00
Scienture Holdings, Inc. Company Information
- Founder, Co-CEO & Executive Chairman
- Shankar Hariharan Ph.D.
- Headquarters
- 20 Austin Boulevard, Commack, NY, United States, 11725
- Website
- scienture.com
- Phone
- 631) 670-6039
- IPO / Founded
- 2010-04-27
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers